Business Context and Reporting Period
Company: AEON Biopharma, Inc. (AEON)
Filing Type: Form 10-Q (Unaudited)
Period Ended: June 30, 2026
Business Overview: AEON is a biopharmaceutical company developing ABP-450, a botulinum toxin complex, as a biosimilar to BOTOX® (onabotulinumtoxinA) for therapeutic indications. The company operates as a single segment focused on research and development (R&D) and holds exclusive rights to commercialize ABP-450 in the U.S. and other territories via an agreement with Daewoong Pharmaceutical Co., Ltd.
Key Financial Metrics
| Metric (in thousands) | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|
| Revenue | $0 | $0 |
| Net (Loss) Income | $(12,948) | $2,453 |
| Operating Loss | $(11,851) | $(4,800) |
| Research & Development Expenses | $4,973 | $1,889 |
| Selling, General & Administrative Expenses | $6,893 | $6,383 |
| Cash and Cash Equivalents (End of Period) | $3,431 | $8,439 |
| Net Cash Used in Operating Activities | $(6,334) | $(10,000) |
| Net Cash Provided by Financing Activities | $6,759 | $18,430 |
| Total Assets | $5,910 | $5,560 |
| Total Liabilities | $21,271 | $60,587 |
| Stockholders' Deficit | $(15,361) | $(55,027) |
Note: The company reported no revenue. Net loss for the six months ended June 30, 2026, was driven by operating expenses and a loss on the fair value of convertible notes, partially offset by gains on the fair value of warrants.
Material Changes vs. Prior Period
- Operating Expenses: Total operating costs increased to $11.9 million from $4.8 million year-over-year. R&D expenses rose 163% to $5.0 million, primarily due to increased biosimilar consulting and payroll expenses. SG&A expenses increased 8% to $6.9 million, driven by stock-based compensation and professional fees.
- Net Income/Loss: The company reported a net loss of $12.9 million compared to net income of $2.5 million in the prior year. The prior year's income was significantly influenced by a $75.6 million loss on warrant issuance and an $86.2 million gain on the change in fair value of warrants, which were not present in the current period to the same magnitude.
- Debt Restructuring: In January 2026, the company exchanged $15.0 million of existing convertible notes held by Daewoong for common stock, pre-funded warrants, a new $1.5 million convertible note, and new warrants. This resulted in a loss on extinguishment of debt of $76,000.
- Warrant Liabilities: The company recognized a $9.6 million gain on the change in fair value of warrants for the six months ended June 30, 2026, compared to an $86.2 million gain in the prior year. The derivative liability of $14.9 million recorded in 2025 was settled in the current period.
- Liquidity: Cash balances decreased from $8.4 million to $3.4 million, despite financing activities, due to operating cash burn.
Guidance, Outlook, Risks, and Unusual Items
- Going Concern: Management has concluded there is substantial doubt about the company's ability to continue as a going concern. As of June 30, 2026, cash was $3.4 million. The company expects to fund operations into the first quarter of 2027, including proceeds from a July 2026 offering, but will require additional capital to complete its development program.
- Recent Financing (Subsequent Event): In July 2026, the company completed an underwritten public offering and over-allotment, receiving net proceeds of approximately $13.6 million. This financing included common stock, pre-funded warrants, and milestone warrants.
- Regulatory Progress: The company held a BPD Type 2a meeting with the FDA in January 2026. The FDA provided constructive feedback on the analytical similarity strategy. The company plans to complete the majority of its analytical comparability program in 2026 and anticipates a BPD Type 2b meeting in the second half of 2026.
- Listing Compliance: The company received notice of noncompliance with NYSE American listing standards due to stockholders' deficit and losses. However, following the July 2026 offering, the company regained compliance as of August 3, 2026.
- Risks: Key risks include the need for substantial additional financing, the uncertainty of regulatory approval for ABP-450, dependency on Daewoong for manufacturing, and potential dilution from outstanding warrants and convertible notes.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $13.6 million raised in July 2026 to fund operations through the planned analytical studies and FDA meetings in 2026 and 2027.
- Dilution Impact: Assess the dilutionary effect of the July 2026 offering, which included pre-funded warrants and milestone warrants, alongside existing PIPE and Daewoong warrants.
- FDA Milestones: Monitor the outcome of the anticipated BPD Type 2b meeting in the second half of 2026, which is critical for the biosimilar development pathway.
- Debt Obligations: Review the terms of the new $1.5 million Daewoong convertible note, including the 15.79% interest rate and conversion triggers tied to future financings or BLA submissions.
- Legal Proceedings: Note the dismissal with prejudice of the lawsuit filed by Aegis Capital Corp. in April 2026 regarding a right of first refusal claim.